Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aura Biosciences Inc
(NQ:
AURA
)
8.580
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
8.580
Bid (Size)
8.650 (2)
Ask (Size)
13.72 (1)
Prev. Close
8.580
Today's Range
8.580 - 8.580
52wk Range
5.990 - 12.35
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aura Biosciences Touts Promising Data From Eye Cancer Candidate
September 12, 2024
Aura Biosciences announced promising Phase 2 results for bel-sar in treating melanoma, achieving 80% tumor control.
Via
Benzinga
AURA Stock Earnings: Aura Biosciences Beats EPS for Q2 2024
August 08, 2024
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-4.98%
-4.98%
1 Month
+16.10%
+16.10%
3 Month
+20.00%
+20.00%
6 Month
+15.95%
+15.95%
1 Year
+3.37%
+3.37%
More News
Read More
AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023
March 27, 2024
Via
InvestorPlace
Recap: Aura Biosciences Q4 Earnings
March 27, 2024
Via
Benzinga
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 27, 2024
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
February 26, 2024
From
Aura Biosciences Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 09, 2024
Via
Benzinga
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
December 07, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying
November 10, 2023
Via
Benzinga
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
November 09, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
November 08, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Why Aura Biosciences Stock Hit A New 52-Week Low Today
November 07, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 07, 2023
Via
Benzinga
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 07, 2023
Via
Benzinga
Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
November 07, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 07, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
November 07, 2023
Via
InvestorPlace
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 07, 2023
Via
Benzinga
Aura Biosciences Announces Pricing of Public Offering of Common Stock
November 06, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
November 06, 2023
Via
Benzinga
Aura Biosciences Announces Proposed Public Offering of Common Stock
November 06, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
November 06, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Top 5 Health Care Stocks That May Fall Off A Cliff This Month
November 06, 2023
Via
Benzinga
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
October 31, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.